open access

Vol 26, No 3 (2019)
Letters to the Editor — Interventional cardiology
Published online: 2019-06-27
Get Citation

Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance

Grzegorz Zuk, Dariusz Ciecwierz, Piotr Drewla, Marcin Gruchała, Juan Luis Gutiérrez-Chico, Milosz Jaguszewski
DOI: 10.5603/CJ.2019.0063
·
Pubmed: 31246271
·
Cardiol J 2019;26(3):304-306.

open access

Vol 26, No 3 (2019)
Letters to the Editor — Interventional cardiology
Published online: 2019-06-27

Abstract

Not available

Abstract

Not available
Get Citation
Supplementary Files (1)
Suppl. Video 1
Download
4MB
About this article
Title

Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance

Journal

Cardiology Journal

Issue

Vol 26, No 3 (2019)

Pages

304-306

Published online

2019-06-27

DOI

10.5603/CJ.2019.0063

Pubmed

31246271

Bibliographic record

Cardiol J 2019;26(3):304-306.

Authors

Grzegorz Zuk
Dariusz Ciecwierz
Piotr Drewla
Marcin Gruchała
Juan Luis Gutiérrez-Chico
Milosz Jaguszewski

References (14)
  1. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009; 5 Suppl F: F15–F22.
  2. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897–910.
  3. Onuma Y, Serruys PW, Perkins LEL, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010; 122(22): 2288–2300.
  4. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014; 7(1): 89–99.
  5. Campos CM, Muramatsu T, Iqbal J, et al. Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. Int J Mol Sci. 2013; 14(12): 24492–24500.
  6. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58(15): 1578–1588.
  7. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385(9962): 43–54.
  8. Muramatsu T, Onuma Y, García-García HM, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013; 6(3): 247–257.
  9. Ormiston JA, Webber B, Ubod B, et al. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. EuroIntervention. 2015; 10(10): 1169–1177.
  10. Ormiston JA, Webber B, Ubod B, et al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015; 11(1): 60–67.
  11. Derimay F, Souteyrand G, Motreff P, et al. Sequential proximal optimizing technique in provisional bifurcation stenting with everolimus-eluting bioresorbable vascular scaffold: fractal coronary bifurcation bench for comparative test between absorb and XIENCE xpedition. JACC Cardiovasc Interv. 2016; 9(13): 1397–1406.
  12. Rivero F, Bastante T, Cuesta J, et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol. 2015; 31(3): 255–259.
  13. Moscarella E, Ielasi A, Granata F, et al. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience. Circ Cardiovasc Interv. 2016; 9(4): e003148.
  14. Jamshidi P, Nyffenegger T, Sabti Z, et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016; 11(13): 1479–1486.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl